TRVI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 24.37%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $897,979.71

Trevi Therapeutics Insider Trading History Chart

Trevi Therapeutics Share Price & Price History

^$6.75

▲ +0.46 (7.31%)

As of 03/14/2025 05:00 PM ET

Days: 30 | 90 | 365

Trevi Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/10/2025	Farrell Simon	Insider	Sell	81,313	$6.75	$548,862.75	76,900
9/9/2024	Jennifer L Good	CEO	Sell	1,840	$3.04	$5,593.60	213,313
9/6/2024	Jennifer L Good	CEO	Sell	4,219	$3.03	$12,783.57	213,313
9/4/2024	Jennifer L Good	CEO	Sell	10,981	$3.02	$33,162.62	213,313
8/27/2024	David P Meeker	Director	Sell	4,555	$2.93	$13,346.15	352,489
8/16/2024	Thomas Sciascia	Insider	Sell	18,660	$2.76	$51,501.60	220,315
8/14/2024	Thomas Sciascia	Insider	Sell	100	$2.75	$275.00	220,315
5/29/2024	Thomas Sciascia	Insider	Sell	53,368	$2.55	$136,088.40	214,433
5/22/2024	Lisa Delfini	CFO	Sell	4,350	$2.64	$11,484.00	53,279
5/20/2024	Jennifer L Good	CEO	Sell	25,037	$2.86	$71,605.82	213,313
5/10/2024	Jennifer L Good	CEO	Sell	4,578	$2.90	$13,276.20	213,313
10/11/2023	Lisa Delfini	CFO	Sell	785	$2.02	$1,585.70	35,901
9/11/2023	Lisa Delfini	CFO	Sell	711	$2.20	$1,564.20	34,394
8/11/2023	Lisa Delfini	CFO	Sell	682	$2.36	$1,609.52	32,814
7/11/2023	Lisa Delfini	CFO	Sell	687	$2.34	$1,607.58	31,204
6/12/2023	Lisa Delfini	CFO	Sell	610	$2.64	$1,610.40	29,599
4/11/2023	Lisa Delfini	CFO	Sell	840	$1.84	$1,545.60	26,189
3/13/2023	Lisa Delfini	CFO	Sell	892	$1.75	$1,561.00	24,737
2/13/2023	Lisa Delfini	CFO	Sell	8,474	$2.45	$20,761.30	23,338
7/5/2022	Tpg Gp A, Llc	Major Shareholder	Sell	63,569	$3.11	$197,699.59	3,824,883
7/1/2022	Tpg Gp A, Llc	Major Shareholder	Sell	436,431	$2.86	$1,248,192.66	3,888,452
6/29/2022	Tpg Gp A, Llc	Major Shareholder	Sell	46,128	$2.74	$126,390.72	4,754,721
5/2/2022	Tpg Gp A, Llc	Major Shareholder	Sell	600	$2.70	$1,620.00	4,800,849
4/28/2022	Tpg Gp A, Llc	Major Shareholder	Sell	7,271	$2.77	$20,140.67	4,817,612
4/11/2022	Paul Edward Walker	Major Shareholder	Buy	3,580,526	$1.90	$6,802,999.40	10,421,428

See Full Table

SEC Filings (Institutional Ownership Changes) for Trevi Therapeutics (NASDAQ:TRVI)

95.76% of Trevi Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Trevi Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/18/2025	Frazier Life Sciences Management L.P.	10,664,774	$43.94M	1.8%	+44.5%	13.874%
2/17/2025	VR Adviser LLC	1,266,457	$5.22M	0.4%	-63.0%	1.648%
2/17/2025	Woodline Partners LP	3,212,597	$13.24M	0.1%	+429.9%	4.179%
2/17/2025	Squarepoint Ops LLC	14,059	$58K	0.0%	N/A	0.018%
2/17/2025	Two Sigma Advisers LP	15,900	$66K	0.0%	N/A	0.021%
2/17/2025	Two Sigma Investments LP	135,807	$0.56M	0.0%	N/A	0.177%
2/17/2025	Point72 Asset Management L.P.	4,150,237	$17.10M	0.0%	N/A	5.399%
2/17/2025	ProShare Advisors LLC	20,685	$85K	0.0%	+86.4%	0.027%
2/17/2025	MPM Bioimpact LLC	3,094,896	$12.75M	1.8%	+101.2%	4.026%
2/17/2025	Millennium Management LLC	180,419	$0.74M	0.0%	+774.9%	0.235%
2/17/2025	Cubist Systematic Strategies LLC	89,309	$0.37M	0.0%	N/A	0.116%
2/17/2025	Bridgeway Capital Management LLC	177,481	$0.73M	0.0%	-4.3%	0.231%
2/17/2025	Cantor Fitzgerald L. P.	20,000	$82K	0.0%	N/A	0.026%
2/17/2025	BNP Paribas Financial Markets	7,686	$32K	0.0%	-35.6%	0.010%
2/17/2025	Ameriprise Financial Inc.	96,784	$0.40M	0.0%	+187.0%	0.126%
2/17/2025	Algert Global LLC	14,779	$61K	0.0%	-39.9%	0.019%
2/17/2025	Ally Bridge Group NY LLC	781,489	$3.22M	2.7%	-40.9%	1.017%
2/17/2025	Acorn Capital Advisors LLC	2,001,048	$8.24M	4.5%	N/A	2.603%
2/17/2025	Acuta Capital Partners LLC	771,958	$3.18M	3.2%	+165.7%	1.004%
2/14/2025	Northern Trust Corp	482,815	$1.99M	0.0%	+11.3%	0.628%
2/14/2025	Boothbay Fund Management LLC	93,859	$0.39M	0.0%	N/A	0.122%
2/14/2025	Adage Capital Partners GP L.L.C.	2,500,000	$10.30M	0.0%	N/A	3.252%
2/14/2025	Price T Rowe Associates Inc. MD	25,166	$0.10M	0.0%	+32.1%	0.033%
2/14/2025	Silverarc Capital Management LLC	734,234	$3.03M	0.7%	+52.1%	0.955%
2/14/2025	Vivo Capital LLC	3,487,903	$14.37M	1.6%	+116.3%	4.537%
2/14/2025	MetLife Investment Management LLC	38,785	$0.16M	0.0%	+104.9%	0.050%
2/14/2025	Dimensional Fund Advisors LP	134,353	$0.55M	0.0%	+86.1%	0.175%
2/13/2025	Marshall Wace LLP	42,921	$0.18M	0.0%	-47.1%	0.056%
2/13/2025	Jump Financial LLC	21,589	$89K	0.0%	N/A	0.028%
2/13/2025	Walleye Capital LLC	33,097	$0.14M	0.0%	N/A	0.043%
2/13/2025	XTX Topco Ltd	67,201	$0.28M	0.0%	N/A	0.087%
2/13/2025	Barclays PLC	156,267	$0.64M	0.0%	+64.1%	0.203%
2/13/2025	Summit Investment Advisors Inc.	6,332	$26K	0.0%	+84.2%	0.008%
2/13/2025	Raymond James Financial Inc.	12,000	$49K	0.0%	N/A	0.016%
2/13/2025	Renaissance Technologies LLC	100,400	$0.41M	0.0%	+42.0%	0.131%
2/13/2025	Invesco Ltd.	23,621	$97K	0.0%	+21.2%	0.031%
2/13/2025	Wells Fargo & Company MN	33,050	$0.14M	0.0%	+40.7%	0.043%
2/12/2025	Landscape Capital Management L.L.C.	52,085	$0.22M	0.0%	-87.7%	0.068%
2/12/2025	Geode Capital Management LLC	1,299,322	$5.35M	0.0%	+2.8%	1.690%
2/12/2025	JPMorgan Chase & Co.	221,664	$0.91M	0.0%	+120.5%	0.288%
2/11/2025	American Century Companies Inc.	78,143	$0.32M	0.0%	+44.7%	0.102%
2/11/2025	Rosalind Advisors Inc.	1,062,500	$4.38M	2.2%	+41.7%	1.382%
2/10/2025	Tejara Capital Ltd	153,739	$0.63M	0.4%	-36.4%	0.200%
2/6/2025	Raymond James Financial Inc.	12,000	$49K	0.0%	N/A	0.016%
2/6/2025	Charles Schwab Investment Management Inc.	173,063	$0.71M	0.0%	+14.7%	0.225%
2/4/2025	Bank of New York Mellon Corp	140,219	$0.58M	0.0%	+2.1%	0.182%
1/24/2025	China Universal Asset Management Co. Ltd.	16,298	$67K	0.0%	N/A	0.021%
1/17/2025	SG Americas Securities LLC	26,792	$0.11M	0.0%	+14.5%	0.035%
12/26/2024	JPMorgan Chase & Co.	100,517	$0.34M	0.0%	+220.6%	0.131%
11/19/2024	Barclays PLC	95,232	$0.32M	0.0%	+180.8%	0.124%
11/16/2024	Geode Capital Management LLC	1,264,166	$4.22M	0.0%	+10.2%	1.645%
11/15/2024	Barclays PLC	95,232	$0.32M	0.0%	+180.8%	0.124%
11/15/2024	Jane Street Group LLC	32,929	$0.11M	0.0%	-50.4%	0.043%
11/15/2024	State Street Corp	952,912	$3.18M	0.0%	+5.9%	1.240%
11/15/2024	Checkpoint Capital L.P.	250,000	$0.84M	0.4%	-50.0%	0.325%
11/14/2024	Fred Alger Management LLC	76,544	$0.26M	0.0%	N/A	0.100%
11/14/2024	Ally Bridge Group NY LLC	1,322,800	$4.42M	2.4%	-10.3%	1.721%
11/14/2024	Acuta Capital Partners LLC	290,500	$0.97M	0.8%	+11.7%	0.378%
11/13/2024	BNP Paribas Financial Markets	11,930	$40K	0.0%	+130.9%	0.016%
11/9/2024	Landscape Capital Management L.L.C.	424,725	$1.42M	0.1%	-29.8%	0.585%
11/9/2024	Intech Investment Management LLC	18,914	$63K	0.0%	N/A	0.026%
11/7/2024	MAI Capital Management	1,327,285	$4.43M	0.0%	+0.7%	1.828%
11/6/2024	Oppenheimer & Co. Inc.	81,947	$0.27M	0.0%	+34.7%	0.113%
11/5/2024	GSA Capital Partners LLP	122,447	$0.41M	0.0%	N/A	0.169%
10/30/2024	Rosalind Advisors Inc.	750,000	$2.51M	1.6%	-46.1%	1.033%
10/3/2024	SG Americas Securities LLC	23,405	$78K	0.0%	N/A	0.033%
8/15/2024	The Manufacturers Life Insurance Company	24,524	$73K	0.0%	+87.6%	0.035%
8/14/2024	Logos Global Management LP	2,800,000	$8.34M	0.7%	+27.3%	3.975%
8/14/2024	Ally Bridge Group NY LLC	1,474,926	$4.40M	2.6%	N/A	2.094%
8/13/2024	Rubric Capital Management LP	5,026,931	$14.98M	0.4%	-9.7%	7.137%
8/12/2024	Hsbc Holdings PLC	19,612	$61K	0.0%	N/A	0.028%
8/9/2024	Renaissance Technologies LLC	51,900	$0.16M	0.0%	-55.6%	0.074%
8/9/2024	Dimensional Fund Advisors LP	72,210	$0.22M	0.0%	+217.6%	0.103%
8/8/2024	American Century Companies Inc.	54,108	$0.16M	0.0%	+17.1%	0.077%
8/1/2024	Rhumbline Advisers	75,218	$0.22M	0.0%	+44.8%	0.107%
7/26/2024	Bank of New York Mellon Corp	178,511	$0.53M	0.0%	+38.8%	0.253%
7/12/2024	Rosalind Advisors Inc.	1,391,577	$4.15M	3.0%	+50.3%	1.976%
5/29/2024	Opaleye Management Inc.	2,645,000	$9.13M	2.0%	+4.3%	3.756%
5/15/2024	Price T Rowe Associates Inc. MD	13,561	$47K	0.0%	N/A	0.019%
5/14/2024	Propel Bio Management LLC	260,000	$0.90M	0.5%	N/A	0.369%
5/10/2024	Vanguard Group Inc.	2,303,648	$7.95M	0.0%	+2.7%	3.271%
5/7/2024	Oppenheimer & Co. Inc.	60,415	$0.21M	0.0%	N/A	0.086%
5/7/2024	SG Americas Securities LLC	14,592	$50K	0.0%	-85.1%	0.021%
5/1/2024	BNP Paribas Financial Markets	20,577	$71K	0.0%	-84.4%	0.030%
4/25/2024	Rosalind Advisors Inc.	926,016	$3.20M	3.0%	-50.3%	1.343%
2/15/2024	Opaleye Management Inc.	2,535,000	$3.40M	0.9%	+48.6%	3.970%
2/15/2024	Frazier Life Sciences Management L.P.	7,381,090	$9.89M	0.5%	+7.3%	11.559%
2/5/2024	WealthTrust Axiom LLC	63,500	$85K	0.0%	-32.1%	0.099%
1/12/2024	SG Americas Securities LLC	98,253	$0.13M	0.0%	+401.4%	0.154%
1/4/2024	Trust Co. of Toledo NA OH	36,502	$49K	0.0%	-68.8%	0.057%
11/13/2023	Silverarc Capital Management LLC	927,415	$2.02M	0.6%	+4.7%	1.452%
10/20/2023	Trust Co. of Toledo NA OH	117,145	$0.26M	0.1%	-6.2%	0.183%
10/13/2023	SG Americas Securities LLC	19,597	$43K	0.0%	N/A	0.031%
9/21/2023	Barclays PLC	14,052	$34K	0.0%	N/A	0.022%
8/11/2023	VR Adviser LLC	3,422,397	$8.18M	1.3%	+12.2%	5.697%
8/11/2023	Tejara Capital Ltd	180,227	$0.43M	0.2%	-5.3%	0.300%
8/4/2023	American International Group Inc.	20,037	$48K	0.0%	N/A	0.033%
8/3/2023	Innovis Asset Management LLC	43,232	$0.10M	0.0%	-50.5%	0.072%
8/2/2023	MAI Capital Management	1,534,652	$3.67M	0.1%	-4.1%	2.555%
7/10/2023	Trust Co. of Toledo NA OH	124,857	$0.30M	0.1%	+50.4%	0.208%

Data available starting January 2016

See Full Table

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $6.75

$6.28

$6.78

50 Day Range

MA: $4.35

$3.56

$6.75

52 Week Range

Now: $6.75

$2.30

$7.39

Volume

1,915,221 shs

Average Volume

2,023,841 shs

Market Capitalization

$518.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Who are the company insiders with the largest holdings of Trevi Therapeutics?: Trevi Therapeutics' top insider investors include:
David P Meeker (Director)
Thomas Sciascia (Insider)
Jennifer L Good (CEO)
Farrell Simon (Insider)
Lisa Delfini (CFO)
Learn More about top insider investors at Trevi Therapeutics.
Who are the major institutional investors of Trevi Therapeutics?: Trevi Therapeutics' top institutional shareholders include:
Frazier Life Sciences Management L.P. — 13.87%
Point72 Asset Management L.P. — 5.40%
Vivo Capital LLC — 4.54%
Woodline Partners LP — 4.18%
MPM Bioimpact LLC — 4.03%
Adage Capital Partners GP L.L.C. — 3.25%
Learn More about top institutional investors of Trevi Therapeutics stock.
Which major investors are selling Trevi Therapeutics stock?: In the last quarter, TRVI stock was sold by these institutional investors:
VR Adviser LLC
Ally Bridge Group NY LLC
Landscape Capital Management L.L.C.
Tejara Capital Ltd
Marshall Wace LLP
Algert Global LLC
Bridgeway Capital Management LLC
Citadel Advisors LLC
During the last year, company insiders that have sold Trevi Therapeutics company stock include:
David P Meeker (Director)
Thomas Sciascia (Insider)
Jennifer L Good (CEO)
Farrell Simon (Insider)
Lisa Delfini (CFO)
Learn More investors selling Trevi Therapeutics stock.
Which major investors are buying Trevi Therapeutics stock?: Within the last quarter, TRVI stock was purchased by institutional investors including:
Point72 Asset Management L.P.
Frazier Life Sciences Management L.P.
Woodline Partners LP
Adage Capital Partners GP L.L.C.
Acorn Capital Advisors LLC
Vivo Capital LLC
MPM Bioimpact LLC
Acuta Capital Partners LLC